- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2466
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF) ; volume:21 ; number:1 ; day:5 ; month:1 ; year:2021 ; pages:1-6 ; date:12.2021
BMC pulmonary medicine ; 21, Heft 1 (5.1.2021), 1-6, 12.2021
- Creator
-
Epstein Shochet, Gali
Israeli-Shani, Lilach
Kains, Isabelle
Wand, Ori
Shitrit, David
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12890-020-01377-3
- URN
-
urn:nbn:de:101:1-2021030923325195891820
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Epstein Shochet, Gali
- Israeli-Shani, Lilach
- Kains, Isabelle
- Wand, Ori
- Shitrit, David
- SpringerLink (Online service)
Other Objects (12)
Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)
The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
Idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)
The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
Idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)
The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
Idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis